Blog
Archive: October 2025
Advancing AD Trials: Integrating Plasma Biomarkers and Imaging for Precision Enrolment
The development of blood-based biomarkers (BBMs) for early detection of Alzheimer’s disease (AD) pathology is transformative for research and drug development. Historically, diagnosis relied on symptomatic presentation with costly confirmatory imaging. Today, the field is shifting toward a biologically defined framework for earlier detection and trial stratification.
Harnessing Neuroimaging in Parkinson’s Disease Clinical Trials: Best Practices and Emerging Standards
As clinical research in Parkinson’s Disease (PD) continues to evolve, neuroimaging has become a cornerstone in trial design, patient selection, and therapeutic evaluation. Across the industry, sponsors and imaging partners are adopting increasingly sophisticated imaging strategies to enhance data quality, regulatory compliance, and scientific insight.